Fibrinogen B β promoter polymorphism may not be associated with pulmonary embolism

Abstract

Objective

A prospective experiment was designed to explore all possible SNPs in the promoter region of fibrinogen B β (FGB) and reveal the influence of these SNPs on susceptibility of pulmonary embolism.

Methods

In this 2-year randomized prospective study, we had totally recruited 203 volunteers. 58 PE patients (58 out of 145 VTE patients) and 114 healthy people were taken as case and control objects, respectively. FGB promoter was detected by gene sequencing.

Results

There were 6 SNPs in FGB promoter, which were β-1420G/A, β-993C/T, β-854G/A, β-455G/A, β-249C/T, and β-148C/T. Genotype frequencies of individual SNPs between the cases and controls were not statistically significant, all p > .05. After excluding subjects of COVID-19 infection within 6 months, the statistical results (35 PE patients vs 66 healthy people) were consistent.

Conclusion

The susceptibility to pulmonary embolism may not be affected by any SNP in the FGB promoter region.

Keywords

Fibrinogen β single nucleotide polymorphisms pulmonary embolism fibrinogen B β promoter polymorphism

Get full access to this article

View all access options for this article.

References

Cohen

Agnelli

Anderson

VTE Impact Assessment Group in Europe VITAE , et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemostasis 2007; 98(4): 756–764.

Wendelboe

Raskob

. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016; 118: 1340–1347.

Lutsey

Zakai

. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol 2022; 20: 248–262.

Mosesson

Siebenlist

Meh

. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11–30.

van ’t Hooft

von Bahr

Silveira

, et al. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol 1999; 19: 3063–3070.

Anderson

Jr Spencer

. Risk factors for venous thromboembolism. Circulation 2003; 107: I9–I16.

de Haan

Bezemer

Doggen

, et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120: 656–663.

Gialeraki

Politou

Rallidis

, et al. Prevalence of prothrombotic polymorphisms in Greece. Genet Test 2008; 12: 541–547.

Mosesson

. Fibrinogen and fibrin structure and functions. J Thromb Haemostasis 2005; 3: 1894–1904.

10.

Stevens

Woller

Baumann Kreuziger

, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160: 2247–2259.

11.

Anderson

Zayaruzny

Heit

, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 777–782.

12.

Wiener

Schwartz

Woloshin

. Time trends in pulmonary embolism in the United States: evidence of overdiagnosis. Arch Intern Med 2011; 171: 831–837.

13.

Yang

Liang

Zhai

Investigators for National Cooperative Project for Prevention and Treatment of PTE-DVT , et al. Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One 2011; 6: e26861.

14.

Fajgenbaum

June

. Cytokine storm. N Engl J Med 2020; 383: 2255–2273.

15.

Weisel

Litvinov

. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemostasis 2019; 17: 271–282.

16.

Parakh

Sabath

. Venous thromboembolism: role of the clinical laboratory in diagnosis and management. J Appl Lab Med 2019; 3: 870–882.

17.

Kearon

de Wit

Parpia

PEGeD Study Investigators , et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med 2019; 381: 2125–2134.

18.

Nalbandian

Sehgal

Gupta

, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615.

19.

Poor

. Pulmonary thrombosis and thromboembolism in COVID-19. Chest 2021; 160: 1471–1480.

20.

Rodríguez

Luque

Blanco

, et al. Pulmonary endothelial dysfunction and thrombotic complications in patients with COVID-19. Am J Respir Cell Mol Biol 2021; 64: 407–415.